Precision epidemiology informing the drug development lifecycle.


Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.


Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.

We can help you with:


Determining disease prevalence to clearly define the patient population and establish development priorities.
Clinical Trials

Defining the most relevant patient groups to include in trials.
Market Access and Launch

Providing quantitative evidence of the potential impact of a drug on reducing disease burden, to support HEOR teams with pricing, reimbursement, and market access.
Post-Market Surveillance and Market Expansion Producing post-launch burden of disease studies to demonstrate the impact of new therapies on public health, and quantifying the health, economic, and environmental outcomes of proposed interventions.
Patient Engagement and Advocacy Tailoring marketing strategies to highlight addressing unmet needs, and helping patient education campaigns raise awareness.

From molecule to market, our solutions can help.

Helping you at every stage

From informing early-stage R&D decisions through to market access and launch, contact us to discuss how our data-driven epidemiology can support your product development, strategic planning and portfolio management.

Why Us?

Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.

Why Us?

How do we do it?

We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.


Whats our Track Record?

We’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.

Track Record


Our experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.

About Us

HealthLumen Blog

World Kidney Day 2024: Kidney health for all

It is estimated that a staggering 1 in 10 people worldwide are living with kidney disease (1). Despite its high global prevalence and mortality, CKD has surprisingly often been overlooked on health agendas across the globe up until now. In particular, low and middle-income countries are disproportionately affected by CKD and kidney failure, with a […]


How rare is rare? Quantifying the hidden population living with rare genetic diseases using genetic databases

Rare Disease Day is fast approaching, with a programme of activity being lined up, through international initiatives and country-specific programmes, in the UK for example to highlight challenges, raise awareness and generate change for the 300 million people worldwide living with one or more of the roughly 8,000 known rare diseases, as well as their […]


Join us at upcoming conferences to discuss the latest findings in the epidemiology of rare diseases.

It’s a well-established truism that rare diseases, whilst rare at the individual disease level, are collectively quite common, with some 300 million people worldwide living with a rare disease. However, are rare diseases actually as rare at the individual disease level as current estimates suggest  – what could be the extent of the “hidden population”? […]


NEWS: Policy interventions could reduce chronic liver disease and liver cancer in Europe by up to 7% by 2030 

Europe has the largest burden of diagnosed liver disease globally with almost 30 million people in the European Union alone estimated to be living with a chronic liver condition. Liver cirrhosis accounts for 1.8% of all deaths reported in Europe (170,000 deaths annually) with a 100% increase in cirrhosis deaths observed across the Eastern European […]